OMCL Stock Analysis: Omnicell | NASDAQ
Health Information Services | NASDAQ, USA | Market Cap: 2.077m USD | 12M Return: 71.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.0M
EPS Trend: -18.2%
Qual. Beats: 1
Rev. Trend: 13.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Omnicell, Inc. (NASDAQ: OMCL) is a U.S.-based healthcare technology company that sells medication management and pharmacy automation solutions to hospitals, health systems, retail and community pharmacies in the United States and internationally. Its product portfolio spans automated dispensing cabinets (e.g., Titan XT and XTExtend), central pharmacy and IV compounding automation, specialty pharmacy enablement, medication adherence packaging, and the cloud-based OmniSphere platform, supported by implementation, training, and post-installation maintenance services. The company was incorporated in 1992, is headquartered in Fort Worth, Texas, and trades on the NASDAQ as a small-cap stock in the GICS Health Care Technology sub-industry.
- Hospital capital spending slowdown pressures equipment revenue
- EnlivenHealth platform drives recurring subscription growth
- Competition from BD intensifies in medication automation
| Net Income: 20.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.16 > 1.0 |
| NWC/Revenue: 18.28% < 20% (prev 20.44%; Δ -2.16% < -1%) |
| CFO/TA 0.08 > 3% & CFO 155.9m > Net Income 20.4m |
| Net Debt (-54.5m) to EBITDA (124.7m): -0.44 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.9m) vs 12m ago -1.40% < -2% |
| Gross Margin: 43.50% > 18% (prev 43.24%; Δ 0.26% > 0.5%) |
| Asset Turnover: 58.96% > 50% (prev 52.79%; Δ 6.17% > 0%) |
| Interest Coverage Ratio: 11.43 > 6 (EBIT TTM 41.3m / Interest Expense TTM 3.61m) |
| A: 0.11 (Total Current Assets 706.9m - Total Current Liabilities 483.0m) / Total Assets 2.00b |
| B: 0.20 (Retained Earnings 396.3m / Total Assets 2.00b) |
| C: 0.02 (EBIT TTM 41.3m / Avg Total Assets 2.08b) |
| D: 1.68 (Book Value of Equity 1.26b / Total Liabilities 747.5m) |
| Altman-Z'' = 3.28 = A |
| DSRI: 0.97 (Receivables 264.2m/251.6m, Revenue 1.23b/1.14b) |
| GMI: 0.99 (GM 43.24% / 43.50%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.54) |
| SGI: 1.08 (Revenue 1.23b / 1.14b) |
| TATA: -0.07 (NI 20.4m - CFO 155.9m) / TA 2.00b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 16, 2026, the stock is trading at USD 46.82 with a total of 571,548 shares traded. Over the past week, the price has changed by +3.77%, over one month by +17.08%, over three months by +24.75% and over the past year by +71.88%.
Current recommended Stop Loss: 43.20 (which is 7.7% or 1.9 ATR below the current price).
Omnicell has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy OMCL.
- StrongBuy: 3
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 61.3 | 30.9% |
P/E Trailing = 103.7955
P/E Forward = 29.4985
P/S = 1.6954
P/B = 1.6373
P/EG = 15.3973
Revenue TTM = 1.23b USD
EBIT TTM = 41.3m USD
EBITDA TTM = 124.7m USD
Long Term Debt = 167.9m USD (from longTermDebt, last quarter)
Short Term Debt = 11.6m USD (from shortTermDebt, last quarter)
Debt = 236.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 34.3m
Net Debt = -54.5m USD (calculated: Debt 236.5m - CCE 291.0m)
Enterprise Value = 2.02b USD (2.08b + Debt 236.5m - CCE 291.0m)
Interest Coverage Ratio = 11.43 (Ebit TTM 41.3m / Interest Expense TTM 3.61m)
EV/FCF = 18.10x (Enterprise Value 2.02b / FCF TTM 111.8m)
FCF Yield = 5.53% (FCF TTM 111.8m / Enterprise Value 2.02b)
FCF Margin = 9.12% (FCF TTM 111.8m / Revenue TTM 1.23b)
Net Margin = 1.67% (Net Income TTM 20.4m / Revenue TTM 1.23b)
Gross Margin = 43.50% ((Revenue TTM 1.23b - Cost of Revenue TTM 692.2m) / Revenue TTM)
Gross Margin QoQ = 45.30% (prev 41.51%)
Tobins Q-Ratio = 1.01 (Enterprise Value 2.02b / Total Assets 2.00b)
Interest Expense / Debt = 1.53% (Interest Expense 3.61m / Debt 236.5m)
Taxrate = 45.89% (17.3m / 37.8m)
NOPAT = 22.4m (EBIT 41.3m * (1 - 45.89%))
Current Ratio = 1.46 (Total Current Assets 706.9m / Total Current Liabilities 483.0m)
Debt / Equity = 0.19 (Debt 236.5m / totalStockholderEquity, last quarter 1.26b)
Debt / EBITDA = -0.44 (Net Debt -54.5m / EBITDA 124.7m)
Debt / FCF = -0.49 (Net Debt -54.5m / FCF TTM 111.8m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.98% (Net Income 20.4m / Total Assets 2.00b)
RoE = 1.64% (Net Income TTM 20.4m / Total Stockholder Equity 1.24b)
RoCE = 2.93% (EBIT 41.3m / Capital Employed (Equity 1.24b + L.T.Debt 167.9m))
RoIC = 1.52% (NOPAT 22.4m / Invested Capital 1.47b)
WACC = 6.80% (E(2.08b)/V(2.31b) * Re(7.48%) + D(236.5m)/V(2.31b) * Rd(1.53%) * (1-Tc(0.46)))
Discount Rate = 7.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -0.13 | Cagr: 0.44%
[DCF] Terminal Value 74.87% ; FCFF base≈113.7m ; Y1≈110.2m ; Y5≈108.9m
[DCF] Fair Price = 38.72 (EV 1.71b - Net Debt -54.5m = Equity 1.76b / Shares 45.5m; r=8.35% [WACC [floored]]; 5y FCF grow -4.10% → 2.50% )
EPS Correlation: -18.15 | EPS CAGR: -2.66% | SUE: 1.62 | # QB: 1
Revenue Correlation: 13.00 | Revenue CAGR: 0.68% | SUE: 0.74 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.47 | Chg30d=+12.98% | Revisions=+70% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.47 | Chg30d=-2.33% | Revisions=-38% | Analysts=8
EPS current Year (2026-12-31): EPS=1.94 | Chg30d=+10.35% | Revisions=+67% | GrowthEPS=+19.6% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=2.19 | Chg30d=+5.15% | Revisions=+30% | GrowthEPS=+13.3% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +46% (up=19, down=6)